Biological profile of the less lipophilic and synthetically more accessible bryostatin 7 closely resembles that of bryostatin 1

ACS Chemical Biology

Volumn 8, Issue 4, 2013, Pages 767-777

  Kedei, Noemi ^a   Lewin, Nancy E ^a   Géczy, Tamás ^a   Selezneva, Julia ^a   Braun, Derek C ^a   Chen, Jinqiu ^a   Herrmann, Michelle A ^a   Heldman, Madeleine R ^a   Lim, Langston ^a   Mannan, Poonam ^a   Garfield, Susan H ^a   Poudel, Yam B ^b   Cummins, Thomas J ^b   Rudra, Arnab ^b   Blumberg, Peter M ^a   Keck, Gary E ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRYOSTATIN; BRYOSTATIN 1; BRYOSTATIN 7; PHORBOL ESTER; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; BUGULA NERITINA; CONTROLLED STUDY; HAMSTER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; LEUKEMIA CELL; LIPOPHILICITY; MARINE SPECIES; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

BRYOSTATINS; CELL LINE, TUMOR; DOWN-REGULATION; HUMANS; ISOENZYMES; LIPIDS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; PROTEIN KINASE C; REAL-TIME POLYMERASE CHAIN REACTION; SUBCELLULAR FRACTIONS; U937 CELLS;

BUGULA NERITINA;

EID: 84876583883     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb300671s     Document Type: Article

References (55)

1. Murray, N. R., Thompson, L. J., and Fields, A. P. (1997) The role of protein kinase C in cellular proliferation and cell cycle control, in Molecular Biology Intelligence Unit (Parker, P. J. and Dekker, L. Eds.), pp 97-120, R. G. Landes Co., Austin, TX.
2. Griner, E. M. and Kazanietz, M. G. (2007) Protein kinase C and other diacylglycerol effectors in cancer Nat. Rev. Cancer. 7, 281-294
3. Mackay, H. J. and Twelves, C. J. (2007) Targeting the protein kinase C family: Are we there yet? Nat. Rev. Cancer 7, 554-562
4. Teicher, B. A. (2006) Protein kinase C as a therapeutic target Clin. Cancer Res. 12, 5336-5345
5. Etcheberrigaray, R., Tan, M., Dewachter, I., Kuiperi, C., Van der Auwera, I., Wera, S., Qiao, L., Baank, B., Nelson, T. J., Kozikowski, A. P., Van Leuven, F., and Alkon, D. L. (2004) Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice Proc. Natl. Acad. Sci. U.S.A. 101, 11141-11146
6. Ishii, H., Jirousek, M. R., Koya, D., Takagi, C., Xia, P., Clermont, A., Bursell, S. E, Kern, T. S, Ballas, L. M, Heath, W. F., Stramm, L. E., Feener, E. P., and King, G. L. (1996) Amelioration of vascular dysfunctions in diabetic rats by an oral PKCb inhibitor Science 272, 728-731
7. Roebuck, K. A., Gu, D. S., and Kagnoff, M. F. (1996) Activating protein-1 cooperates with phorbol ester activation signals to increase HIV-1 expression AIDS 10, 819-826
8. Murphy, S. and Frishman, W. H. (2005) Protein kinase C in cardiac disease and as a potential therapeutic target Cardiol. Rev. 13, 3-12
9. Andrejauskas-Buchdunger, E. and Regenass, U. (1992) Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251 Cancer Res. 52, 5353-5358
10. Teicher, B. A., Alvarez, E., Menon, K., Esterman, M. A., Considine, E., Shih, C., and Faul, M. M. (2002) Antiangiogenic effects of a protein kinase Cb-selective small molecule Cancer Chemother. Pharmacol. 49, 69-77
11. Marquez, V. E. and Blumberg, P. M. (2003) Synthetic diacylglycerols (DAG) and DAG-lactones as activators of protein kinase C (PK-C) Acc. Chem. Res. 36, 434-443
12. Zhang, G., Kazanietz, M. G., Blumberg, P. M., and Hurley, J. H. (1995) Crystal structure of the cys2 activator-binding domain of protein kinase C delta in complex with phorbol ester Cell 81, 917-924
13. Heikkilä, J. and Akerman, K. E. (1989) (-)-Indolactam V activates protein kinase C and induces changes in muscarinic receptor functions in SH-SY5Y human neuroblastoma cells Biochem. Biophys. Res. Commun. 15, 1207-1213
14. Hecker, E. (1968) Cocarcinogenic principles from the seed oil of Croton tiglium and from other Euphorbiaceae Cancer Res. 28, 2338-2349
15. Bögi, K., Lorenzo, P. S., Szállási, Z., Acs, P., Wagner, G. S., and Blumberg, P. M. (1998) Differential selectivity of ligands for the C1a and C1b phorbol ester binding domains of protein kinase Cdelta: possible correlation with tumor-promoting activity Cancer Res. 58, 1423-1428
16. Szallasi, Z., Krsmanovic, L., and Blumberg, P. M. (1993) Nonpromoting 12-deoxyphorbol 13-esters inhibit phorbol 12-myristate 13-Acetate induced tumor promotion in CD-1 mouse skin Cancer Res. 53, 2507-2512
17. Zayed, S., Sorg, B., and Hecker, E. (1984) Structure activity relations of polyfunctional diterpenes of the tigliane type, VI. Irritant and tumor promoting activities of semisynthetic mono and diesters of 12-deoxyphorbol Planta Med. 50, 65-69
18. Nakagawa, Y., Irie, K., Nakamura, Y., Ohigashi, H., and Hayashi, H. (1998) Synthesis and biological activities of (-)-6-n-octyl-indolactam-V, a new potent analogue of the tumor promoter (-)-indolactam-V Biosci. Biotechnol. Biochem. 62, 1568-1573
19. Wang, Q. J., Bhattacharyya, D., Garfield, S., Nacro, K., Marquez, V. E., and Blumberg, P. M. (1999) Differential localization of protein kinase C delta by phorbol esters and related compounds using a fusion protein with green fluorescent protein J. Biol. Chem. 274, 37233-37239
20. Kedei, N., Lubart, E., Lewin, N. E., Telek, A., Lim, L., Mannan, P., Garfield, S. H., Kraft, M. B., Keck, G. E., Kolusheva, S., Jelinek, R., and Blumberg, P. M. (2011) Some phorbol esters might partially resemble bryostatin 1 in their actions on LNCaP prostate cancer cells and U937 leukemia cells ChemBioChem 12, 1242-1251
21. Wang, Q. J., Fang, T. W., Fenick, D., Garfield, S., Bienfait, B., Marquez, V. E., and Blumberg, P. M. (2000) The lipophilicity of phorbol esters as a critical factor in determining the pattern of translocation of protein kinase C delta fused to green fluorescent protein J. Biol. Chem. 275, 12136-12146
22. 3H]bryostatin 1 and analogs to calcium-dependent and calcium-independent protein kinase C isozymes Mol. Pharmacol. 46, 374-379
23. For further information, see: http://www.clinicaltrials.gov/
24. Spitaler, M., Utz, I., Hilbe, W., Hofmann, J., and Grunicke, H. H. (1998) PKC-independent modulation of multidrug resistance in cells with mutant (V185) but not wild-type (G185) p-glycoprotein by bryostatin 1 Biochem. Pharmacol. 56, 861-869
25. Koutcher, J. A., Motwani, M., Zakian, K. L., Li, X.-K., Matei, C., Dyke, J. P., Ballon, D., Yoo, H.-H., and Schwartz, G. K. (2000) The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow Clin. Cancer Res. 6, 1498-1507
26. Basu, A. and Lazo, J. S. (1992) Sensitization of human cervical carcinoma cells to cis -diaminedichloroplatinum(II) by bryostatin 1 Cancer Res. 52, 3119-3124
27. Mohammad, R. M., Wall, N. R., Dutcher, Julie, A., and Al-Katib, A. M. (2000) The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (chop) chemotherapy improves response in a chop-resistant human diffuse large cell lymphoma xenograft model Clin. Cancer Res. 6, 4950-4956
28. Berkow, R. L. and Kraft, A. S. (1985) Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor Biochem. Biophys. Res. Commun. 131, 1109-1116
29. Bosco, M. C., Rottschafer, S., Taylor, L. S., Ortaldo, J. R., Longo, D. L., and Espinoza-Delgado, I. (1997) The antineoplastic agent bryostatin-1 induces proinflammatory cytokine production in human monocytes: synergy with interleukin-2 and modulation of interleukin-2rγ chain expression Blood 89, 3402-3411
30. Sun, M.-K. and Alkon, D. L. (2005) Dual effects of bryostatin-1 on spatial memory and depression Eur. J. Pharmacol. 512, 43-51
31. Kuzirian, A. M., Epstein, H. T., Gagliardi, C. J., Nelson, T. J., Sakakibara, M., Taylor, C., Scioletti, A. B., and Alkon, D. L. (2006) Bryostatin enhancement of memory in Hermissenda Biol. Bull. 210, 201-214
32. Sun, M.-K. and Alkon, D. L. (2008) Synergistic effects of chronic bryostatin-1 and α-tocopherol on spatial learning and memory in rats Eur. J. Pharmacol. 584, 328-337
33. For further information, see: http://www.brni.org/
34. Mehla, R., Bivalkar-Mehla, S., Zhang, R., Handy, I., Albrecht, H., Giri, S., Nagarkatti, P., Nagarkatti, M., and Chauhan, A. (2012) Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner PLoS One 5, e11160
35. Wender, P. A., Cribbs, C. M., Koehler, K. F., Sharkey, N. A., Herlad, C. L., Kamano, Y., Pettit, G. R., and Blumberg, P. M. (1988) Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C Proc. Natl. Acad. Sci. U.S.A. 85, 7197-7201
36. Pettit, G. R., Kamano, Y., Herald, C. L., and Tozawa, M. (1985) Isolation and structure of bryostatins 5-7 Can. J. Chem. 63, 1204-1208
37. Tallant, E. A., Smith, J. B., and Wallace, R. W. (1987) Bryostatins mimic the effects of phorbol esters in intact human platelets Biochim. Biophys. Acta 929, 40-46
38. Carr, M. E., Jr., Carr, S. L., and Grant, S. (1995) A sensitive platelet activation-based functional assay for the antileukemic agent bryostatin 1 Anticancer Drugs 6, 384-391
39. Keck, G. E., Poudel, Y. B., Cummins, T. J., Rudra, A., and Covel, J. A. (2011) Total synthesis of bryostatin 1 J. Am. Chem. Soc. 133, 744-747
40. Keck, G. E., Covel, J. A., Schiff, T., and Yu, T. (2002) Pyran annulation: asymmetric synthesis of 2,6-disubstituted-4-methylene tetrahydropyrans Org. Lett. 4, 1189-1192
41. 4 Synth. Commun. 14, 267-277
42. Kedei, N., Telek, A., Michalowski, A. M., Kraft, M. B., Li, W., Poudel, Y.B., Rudra, A., Petersen, M. E., Keck, G. E., and Blumberg, P. M. (2012) Comparison of transcriptional response to phorbol ester, bryostatin 1, and bryostatin analogues in LNCaP and U937 cancer cell lines provides insight into their differential mechanism of action Biochem. Pharmacol. 85, 313-324
43. Kedei, N., Telek, A., Czap, A., Lubart, E. S., Czifra, G., Yang, D., Chen, J., Morrison, T., Goldsmith, P. K., Lim, L., Mannan, P., Garfield, S. H., Kraft, M. B, Li, W., Keck, G. E, and Blumberg, P. M. (2011) The synthetic bryostatin analog Merle 23 dissects distinct mechanisms of bryostatin activity in the LNCaP human prostate cancer cell line Biochem. Pharmacol. 81, 1296-1308
44. Kazanietz, M. G., Areces, L. B., Bahador, A., Mischak, H., Goodnight, J., Mushinski, J. F., and Blumberg, P. M. (1993) Characterization of ligand and substrate specificity for the calcium-dependent and calcium-independent protein kinase C isozymes Mol. Pharmacol. 44, 296-307
45. Vrana, J. A., Saunders, A. M., Chellappan, S. P., and Grant, S. (1998) Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937) Differentiation 63, 33-42
46. Meinhardt, G., Roth, J., and Totok, G. (2000) Protein kinase C activation modulates pro- and anti-Apoptotic signaling pathways Eur. J Cell Biol. 79, 824-833
47. Wang, S., Wang, Z., and Grant, S. (2003) Bryostatin 1 and UCN-01 potentiate 1-β-D-Arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms Mol. Pharmacol. 63, 232-242
48. Gould, C. M. and Newton, A. C. (2008) The life and death of protein kinase C Curr. Drug Targets 9, 614-625
49. von Burstin, V. A., Xiao, L., and Kazanietz, M. G. (2010) Bryostatin 1 inhibits phorbol ester-induced apoptosis in prostate cancer cells by differentially modulating protein kinase C (PKC) delta translocation and preventing PKC delta-mediated release of tumor necrosis factor-Alpha Mol. Pharmacol. 78, 325-332
50. Leontieva, O. V. and Black, J. D. (2004) Identification of two distinct pathways of protein kinase C alpha down-regulation in intestinal epithelial cells J. Biol. Chem. 279, 5788-5801
51. Braun, D. C., Garfield, S. H., and Blumberg, P. M. (2005) Analysis by fluorescence resonance energy transfer of the interaction between ligands and protein kinase Cdelta in the intact cell J. Biol. Chem. 280, 8164-8171
52. Caino, M. C., von Burstin, V. A., Lopez-Haber, C., and Kazanietz, M. G. (2011) Differential regulation of gene expression by protein kinase C isozymes determined by genome-wide expression analysis J. Biol. Chem. 286, 11254-11264
53. Keck, G. E., Kraft, M. B., Truong, A. P., Li, W., Sanchez, C. C., Kedei, N., Lewin, N., and Blumberg, P. M. (2008) Convergent assembly of highly potent analogues of bryostatin 1 via pyran annulation: bryostatin look-Alikes that mimic phorbol ester function J. Am. Chem. Soc. 130, 6660-6661
54. Nguyen, U., Squaglia, N., Boge, A., and Fung, P. A. (2011) The Simple Western: a gel-free, blot-free, hands-free Western blotting reinvention Nat. Methods 8, v-vi
55. Kedei, N., Lundberg, D. J., Toth, A., Welburn, P., Garfield, S. H., and Blumberg, P. M. (2004) Characterization of the interaction of ingenol 3-Angelate with protein kinase C Cancer Res. 64, 3243-3255